Our Team

Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented throughput and capability. Our team is comprised of experienced leaders in machine learning, healthcare, neuroscience, and product development. Together, we're building the future of brain health.

Leadership Team

  • Jacob Donoghue, MD PhD

    CEO & Co-Founder

    Jake translates scientific innovation into clinical interventions. He recently completed his MD from Harvard Medical School and PhD in neuroscience from MIT, leading research into the effects of neuroactive compounds on brain network activity. His published works span epilepsy, cognition and machine learning methods for quantifying pharmacological effects on neural activity.

  • Jarrett Revels

    CTO & Co-Founder

    Jarrett has spent his career dedicated to making good science go farther, faster. Prior to co-founding Beacon, his research at MIT spawned new compiler techniques now leveraged by many modern machine learning frameworks. Today, his open-source work continues to help thousands of scientists and engineers carry out new simulations and explore new ideas.

  • Brandon Westover, MD PhD

    Co-Founder

    Brandon is Professor of Neurology at Harvard Medical School, where he directs the BIDMC Critical Care EEG Monitoring Service and the BIDMC Clinical Data AI Center. An internationally renowned clinician scientist, physician, and technical innovator, he has created a legacy of multidisciplinary teams using engineering and AI to tackle the most pressing challenges in brain disease.

  • Sydney Cash, MD PhD

    Co-Founder

    Syd is an Associate Professor at Harvard Medical School and leads the Center for Neurotechnology and Neurorecovery at MGH. He is a pioneer in the development of novel neurotechnology devices and is world-renowned for his impact on the clinical care of patients with epilepsy. His scientific research has produced groundbreaking discoveries into the physiology of seizures, sleep and memory.

Team

  • Alex Arslan

  • Alexander Chan, PhD

  • Ilan Goodman, PhD

  • Yongbo Wang, MBA

  • Jay Pathmanathan, MD PhD

  • Curtis Vogt

  • Eric Hanson, PhD

  • Phillip Alday, PhD

  • Mike Buttery

  • Jayne Nerrie

  • Dave Kleinschmidt, PhD

  • Dan Florey

  • Seth Chapman

  • Michelle Fogerson, PhD

  • Chris de Graaf

  • Matt Alkaitis, MD PhD

  • Kim Laberinto

  • David Little, PhD

  • Dhany Tjiptarto

  • David Klaffenbach

  • Kendal Sandridge

  • Franz Fürbass, PhD

  • Karen Goldthwaite

  • Jason Larson

  • Angelica Patino

  • Dian Fay

  • Megan Means

  • Srihari Sritharan, PhD

  • Laura Edinger

  • Matt Brzezinski

  • Melina Tsitsiklis, PhD

  • Corey Puryear, PhD

  • Michelle Lee

  • Dan Hassin

  • Glenn Moynihan, PhD

  • Eric Davies

  • Mkrtich Vatinyan

  • Antoine Guillot

  • Silvia Frati Savietto

  • Delphine Lemoine

  • Coline Perreau

  • Pierre Dulawa

  • Maya Dorsey

  • Lara Caha

  • Kevin Courdesses

  • Mehdi Haddada

  • Lahib Ouzzine

  • Sammy Robens-Paradise

  • Karolina Blaszczuk

  • Anna Marszalek

  • David Matthews, PhD

Board and Advisors

  • Robin Washington, MBA

    Former CFO, Gilead & Partner-in-Residence, General Catalyst

    Robin is a renowned executive, facilitating financial success and global impact across biopharma and software organizations. She was most recently the Chief Financial Officer at Gilead Sciences, where she oversaw Global Finance, Operations, Investor Relations and IT. In addition to Beacon, Robin currently sits on the board of Salesforce, Honeywell and Alphabet (the parent company of Google).

  • Naveen Rao, PhD

    Former CEO, MosaicML

    Naveen is an entrepreneur, technologist, AI expert, and the founder and CEO of MosaicML (acq. Databricks 2023). He previously founded Nervana Systems (acq. Intel 2016), a startup focused on hardware and software optimizations for neural networks. Nervana formed the basis of Intel AI. Naveen holds a PhD in Computational Neuroscience from Brown University.

  • Andy Beck, MD PhD

    CEO, PathAI

    Andy is the CEO and co-founder of PathAI, the world's leader in computational pathology. In his PhD work at Stanford, he developed one of the first machine-learning based systems for cancer pathology. Before PathAI, Andy completed his clinical training at Stanford and served as a faculty member in the Pathology Department at Beth Israel Deaconess Medical Center.

  • Gaurav Singal, MD

    Former Chief Data Officer, Foundation Medicine

    Gaurav is a clinician and computer scientist who was most recently the Chief Data Officer at Foundation Medicine. There, he oversaw the company’s data platform, linking clinical data, digital pathology images and bio-banked samples with the world's largest cancer genomics dataset. This accelerated R&D for novel therapies and diagnostics, and supported complex clinical decision-making for patients.

Scientific Advisory Board

  • Jacqueline A. French, MD

    Professor, NYU Grossman School of Medicine

    Dr. French is a professor at the NYU Department of Neurology and Comprehensive Epilepsy Center and founder/director of the Epilepsy Study Consortium. She also serves as chief scientific officer at the Epilepsy Foundation and lectures internationally on clinical trials and the use of antiepileptic drugs. Dr. French is past president of the American Epilepsy Society. She earned her MD from Brown University School of Medicine.

  • Maurizio Fava, MD

    Psychiatrist-In-Chief, Department of Psychiatry, MGH

    Dr. Fava founded MGH’s Depression Clinical and Research Program (DCRP) and was director from 1990 to 2014. Under his direction, the DCRP became one of the most highly regarded depression programs in the country. In 2007, Dr. Fava founded the Mass General Psychiatry Clinical Trials Network and Institute, where he serves as executive director. Dr. Fava received his MD from the University of Padova School of Medicine.

  • Thomas Roth, PhD

    Director, Sleep Disorders and Research Center, Henry Ford Hospital

    Dr. Roth has been director of the Sleep Disorders and Research Center since 1978. He was instrumental in the formation of the Association of Sleep Disorders Center (ASDC), serving as the organization’s second president. Dr. Roth won the National Sleep Foundation’s Lifetime Achievement Award for his contributions to sleep science, sleep medicine, and public health. He received his doctorate from the University of Cincinnati.

  • Andrew Krystal, MD

    Professor, University of California, San Francisco

    Dr. Krystal is a professor of psychiatry at the UCSF School of Medicine’s Weill Institute for Neuroscience. He is a pioneer in the application of computational modeling to aid the study of biomarker development using EEG in patients with depression and sleep disorders. Dr. Krystal has been principal investigator of more than 50 single-site and multi-site clinical trials. He received his MD from Duke University School of Medicine.

  • Elaine C. Wirrell, MD

    Director of Pediatric Epilepsy, Mayo Clinic

    Dr. Wirrell’s clinical focus includes early-onset epilepsies and epileptic encephalopathies and medically intractable pediatric epilepsy. She is co-founder of the Pediatric Epilepsy Research Consortium, a multicenter group of pediatric epileptologists who collaborate on clinical research in early-life epilepsies. Dr. Wirrell is director of the Child and Adolescent Neurology Residency Training Program at Mayo Clinic. She received her MD at the University of British Columbia.

  • Dennis Dlugos, MD

    Pediatric Neurologist, Children’s Hospital of Philadelphia

    Dr. Dlugos is a professor of neurology and pediatrics at Children’s Hospital of Philadelphia (CHOP) and University of Pennsylvania School of Medicine. He holds the CHOP Tristram C. Colket, Jr. Endowed Chair in Pediatric Neurology. Epilepsy genetics, pharmacogenetics, intensive Care EEG monitoring, and epilepsy surgery are among his research interests. Dr. Dlugos received his MD from Columbia University College of Physicians and Surgeons.

  • Brendan P. Lucey, MD

    Associate Professor, Washington University

    In addition to his role as an associate professor of neurology, Dr. Lucey is director of Washington University’s Sleep Medicine Center. His research focuses on sleep and Alzheimer’s disease and epilepsy and Alzheimer’s disease. Dr. Lucey currently is heading a study on whether using medication to treat sleep problems in older adults can reduce signs of early Alzheimer’s. He received his MD from Johns Hopkins University.

  • Andrew J. Cole, MD

    Director, MGH Epilepsy Service

    Dr. Cole is chief of the Division of Clinical Neurophysiology and Epilepsy and professor of neurology at Harvard Medical School. He joined Massachusetts General Hospital in 1992, starting and developing the MGH Epilepsy Service and founding the MGH Pediatric Epilepsy Service. Dr. Cole has published extensively in clinical neurology, epilepsy, clinical neurophysiology and basic neuroscience. He received his MD from Dartmouth Medical School.

  • Brian Litt, MD

    Professor, University of Pennsylvania

    A neurologist and entrepreneur, Dr. Litt is a professor of neurology and professor of bioengineering in the Perelman School of Medicine at the University of Pennsylvania. He cofounded two companies (IntelliMedix and Bioquantix), has helped bring several implantable neuro devices to market, and has licensed technology to several companies. Dr. Litt received his MD from Johns Hopkins University School of Medicine.

  • Robert J. Thomas, MD

    Associate Professor, Harvard Medical School

    An associate professor at Harvard Medical School’s Division of Sleep Medicine, Dr. Thomas also is a practicing physician specializing in pulmonary disease and sleep medicine at Beth Israel Deaconess Medical Center. In addition, Dr. Thomas is a visiting scientist at the Martinos Center for Biomedical Imaging, Department of Radiology, at Massachusetts General Hospital. He earned his MD at Madras University School of Medicine.

Our Investors